---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-074266"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T15:26:48.341201+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q3 2022 sales down 7% YoY, net loss of $655K vs prior-year profit; margins hurt by contamination

## Summary
- Q3 2022 product sales of $4.80M, down 7% from $5.15M in Q3 2021; nine-month sales up 6% to $14.66M.
- Net loss of $655K ($0.08/share) in Q3 vs net income of $148K ($0.02/share) a year ago; nine-month net loss $826K.
- Gross margin fell to 38% in Q3 from 47% in prior year due to product contamination events causing inventory write-offs.
- Restated Q1 and Q2 2022 filings to accrue $222K of deferred compensation (PTO); no cash impact.
- FDA submission for Re-Tain CMC Technical Section on track for Q1 2023, subject to six-month review.

## SEC filing metadata
- accession: 0001213900-22-074266
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390022074266/0001213900-22-074266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390022074266/ea169099-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-074266
- JSON: https://secwatch.observer/filing/0001213900-22-074266.json
- Plain text: https://secwatch.observer/filing/0001213900-22-074266.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported the nine-month periods ended September 30, 2022 results: revenue $ 14.66 million, net income ($826,000), EPS ($0.11) per basic share.
  - Period: the nine-month periods ended September 30, 2022
  - Revenue: $ 14.66 million
  - Net income: ($826,000)
  - EPS: ($0.11) per basic share
  - Result: reported results
  source text: (% Decrease ) % Increase During the Three-Month Periods Ended September 30, $ 4.80 million $ 5.15 million $ (354,000 ) (7 )% During the Nine-Month Periods Ended September 30, $ 14.66 million $ 13.80 million $ 858,000 6 % During the Twelve-Month Periods Ended September 30, $ 20.10 million $ 17.54 million $ 2.56 million 15 % Management’s Discussion: “As we work our way
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390022074266/0001213900-22-074266-index.htm
- Earnings Releases
  IMMUCELL CORP /DE/ reported the quarter ended September 30, 2022 results: revenue $ 4.80 million, net income ($655,000), EPS ($0.08) per basic share.
  - Period: the quarter ended September 30, 2022
  - Revenue: $ 4.80 million
  - Net income: ($655,000)
  - EPS: ($0.08) per basic share
  - Result: reported results
  source text: quarter ended September 30, 2022. Unaudited Total Sales Results: 2022 2021 ($ Decrease ) $ Increase (% Decrease ) % Increase During the Three-Month Periods Ended September 30, $ 4.80 million $ 5.15 million $ (354,000 ) (7 )% During the Nine-Month Periods Ended September 30, $ 14.66 million $ 13.80 million $ 858,000 6 % During the Twelve-Month Periods Ended September
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390022074266/0001213900-22-074266-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.